• Increased hepatitis B vaccination rates in various populations (Chapter 4).

  • Improved integration and enhancement of viral hepatitis services for specific at-risk populations and in health-care and other settings (Chapter 5).

REFERENCES

Altekruse, S. F., K. A. McGlynn, and M. E. Reichman. 2009. Hepatocellular carcinoma inci-2009. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. Journal of Clinical Oncology 27(9):1485-1491.

American Cancer Society. 2009. Cancer facts & figures, 2009. Atlanta, GA.

Amon, J. J., R. S. Garfein, L. Ahdieh-Grant, G. L. Armstrong, L. J. Ouellet, M. H. Latka, D. Vlahov, S. A. Strathdee, S. M. Hudson, P. Kerndt, D. Des Jarlais, and I. T. Williams. 2008. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clinical Infectious Diseases 46(12):1852-1858.

Armstrong, G. L., A. Wasley, E. P. Simard, G. M. McQuillan, W. L. Kuhnert, and M. J. Alter. 2006. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Annals of Internal Medicine 144(10):705-714.

Beasley, R., and L. Hwang. 1991. Overview of the epidemiology of heptocellular carcinoma. In Viral hepatitis and liver disease. Proceedings of the 1990 international symposium on viral hepatitis and liver disease, edited by F. B. Hollinger, S. Lemon, and H. S. Margolis. Baltimore: Williams & Wilkins. Pp. 532-525.

Bonacini, M., M. D. Groshen, M. C. Yu, S. Govindarajan, and K. L. Lindsay. 2001. Chronic hepatitis C in ethnic minority patients evaluated in Los Angeles county. American Journal of Gastroenterology 96(8):2438-2441.

Boutwell, A. E., S. A. Allen, and J. D. Rich. 2005. Opportunities to address the hepatitis C epidemic in the correctional setting. Clinical Infectious Diseases 40(s5):S367-S372.

But, D. Y., C. L. Lai, and M. F. Yuen. 2008. Natural history of hepatitis-related hepatocellular carcinoma. World Journal of Gastroenterology 14(11):1652-1656.

CDC (Centers for Disease Control and Prevention). 1998. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Morbidity and Morality Weekly: Recommendations and Reports 47(RR-19):1-39.

———. 2001. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. Morbidity and Morality Weekly: Recommendations and Reports 50(RR-11):1-52.

———. 2004. Incidence of acute hepatitis B—United States, 1990-2002. Morbidity and Mortality Weekly Report 52(51-52):1252-1254.

———. 2006. Screening for chronic hepatitis B among Asian/Pacific Islander populations—New York City, 2005. Morbidity and Mortality Weekly Report 55(18):505-509.

———. 2007. FAQs for health professionals: Hepatitis B. http://www.cdc.gov/hepatitis/HBV/HBVfaq.htm#overview (accessed August 21, 2009).

———. 2008a. Disease burden from hepatitis A, B, and C in the United States. http://www.cdc.gov/hepatitis/statistics.htm (accessed August 21, 2209)

———. 2008b. HIV prevalence estimates—United States, 2006. Morbidity and Mortality Weekly Report 57(39):1073-1076.

———. 2008c. Newborn hepatitis B vaccination coverage among children born January 2003-June 2005—United States. Morbidity and Mortality Weekly Report 57(30):825-828.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement